Tazarotene 0.05%-1.1% (Zorac®);Tazarotène 0,05%-0,1% (Zorac®)

Revue Medicale de Liege

Volumn 58, Issue 11, 2003, Pages 706-708

  Henno, A ^a   Hua, M T ^a   De La Brassinne, M ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Service de Dermatologie   (France)

Author keywords

Psoriasis; Retinoid; Tazarotene

Indexed keywords

RETINOID; TAZAROTENE; DERMATOLOGICAL AGENT; NICOTINIC ACID DERIVATIVE;

ACNE; BELGIUM; DRUG EFFICACY; DRUG INDICATION; DRUG SELECTIVITY; ICHTHYOSIS; PHOTODERMATOSIS; PSORIASIS; REVIEW; UNITED STATES; DOSE RESPONSE; HUMAN; SUNBURN; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ICHTHYOSIS; NICOTINIC ACIDS; PSORIASIS; SUNBURN;

EID: 1642512666     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Krueger GG, Duvic M.- Epidemiology of psoriasis: clinical issues. J Invest Dermatol, 1994, 102, 14S-18S
2. Duvic M, Nagpal S, Chandraratna R et al.- Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol, 1997, 37, S18-S24.
3. Elder JT, Guo S-W et al.- The genetics of psoriasis. Arch Dermatol, 1994, 130, 216-224.
4. th Edition. Mc Graw-Hill, New York, 1999, 495-521.
5. Greaves MW, Weinstein GD.- Treatment of psoriasis. N Engl J Med, 1995, 332, 581-589.
6. Foster RH, Brogden RN, Benfield P.- Tazarotene. Drugs, 1998, 55, 705-711.
7. Weinstein GD.-Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis. Br J Dermatol, 1996, 135 Supp 149, 32-6.
8. Gollnick HPM, Finzi AF, Marks R et al.- Optimizing the use of tazarotene in clinical practice: Consensus statement from the European Advisory Panel for tazarotene. Dermatology, 1999, 199, 40-46.
9. Kenneth G. Linden, Gerald D. Weinstein.- Psoriasis: Current perspectives with an emphasis on treatment. Am J Med, 1999, 107, 595-605.
10. Chandraratna RAS.- Rational design of receptor-selective retinoids. J Am Acad Dermatol, 1998, 39, S124-128.
11. Boehm MF, et al.- Retinoids: biological function and use in the treatment of dermatological diseases. Exp Opin Invest Drugs, 1995, 4, 593-612.
12. Love JM, Gudas LJ.- Vitamin A, differentiation and cancer. Curr Opin Cell Biol, 1994, 6, 825-31.
13. Orfanos EO, Zouboulis CC, et al.- Current and future potential role of retinoids in dermatology. Drugs, 1997, 53, 358-388.
14. Chandraratna RAS.- Tazarotene: the fust receptor-selective topical retinoid for the treatment of psoriasis. J Am Acad Dermatol, 1997, 37 (2 Pt 3), S12-S17.
15. Napgal S, Athanikar J, Chandraratna RAS.- Separation of transactivation and APl antagonism functions of retinoic acid receptor α. J Biol Chem, 1995, 270, 923-927.
16. Tang-Liu DD-S, Matsumoto RM, Usansky JI.- Clinical pharmacokinetics and drug metabolism of tazarotene. Clin Pharmacokinet, 1999, 37, 273-287.
17. Menter A.-Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol, 2000, 43, S31-S35.
18. Weinstein GD, Krueger GG, Lowe NJ et al.- Tazarotene gel, a new retinoid, for topical therapy in psoriasis. vehicle-controlled study of safety and duration of therapeutic effect. J Am Acad Derm, 1997, 37, 85-92.
19. Lebwo W BG, Breneman DL, Goffe S.- Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol, 1998, 39, 590-596.
20. Green L, Sadoff W and the Tazarotene Plus High Potency or Mid-High Potency Steroid Study Group.- Tazarotene O.1% gel, with and without a high potency or mid-high potency corticosteroid, in the treatment of stable plaque psoriasis. Poster presented at the American Academy of Dermatology Meeting, July 28-August 1, 1999, New York City, New York.
21. Kaidbey K, Kopper SC, Sefton J, et al.- A pilot study to determine the effects of tazarotene gel 0.1% on steroid-induced epidermal atrophy. Int J Dermatol, 2001, 40, 468-471.
22. Guenther L.- Tazarotene combination treatment in psoriasis. J Am Acad Dermatol, 2000, 43, S36-S42.
23. Koo JYM, Lowe NJ, Lew-Kaya DA, et al.- Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol, 2000, 43, 821-828.
24. Tzaneva S, Seeber A, Hönigsmann, et al.- A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. Br J Dermatol, 2002, 147, 748-753.
25. Kang S, Leyden JJ, Lowe N, et al.- Tazarotene cream for the treatment of facial photodamage. Arch Dermatol, 2001, 137, 1597-1604.
26. Hoffman B, Stege H, Ruzicka T, et al.- Effect of topical tazarotene in the treatment of congenital ichtyoses. Br J Dermatol, 1999, 141, 642-646.